Organization (Industry)
ILLUMINA, INC.
ClinicalTrials.gov lists ILLUMINA, INC. as lead sponsor of 15 trials, counting the companies grouped under it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Illumina, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers ILLUMINA, INC. and 2 companies grouped under it: 15 lead-sponsored trials (12 its own, 3 in the grouped companies) and 9 legal-entity registrations (7 its own, 2 in the grouped companies).
Companies grouped under this page (2)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Verinata Health, Inc. | 3 | 0 |
| ILLUMINA CAMBRIDGE LIMITED | 0 | 2 |
Disease areas (121)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Anemia | 2 |
| Breast Neoplasms | 2 |
| Coronary Artery Disease | 2 |
| Coronary Disease | 2 |
| Diabetes Mellitus | 2 |
Showing 5 of 121 disease areas.
Trials by start year as sponsor or collaborator (13)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2023 | 4 |
| 2022 | 4 |
| 2021 | 3 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 2 |
| 2017 | 2 |
| 2016 | 1 |
| 2014 | 1 |
Showing 10 of 13 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 63% hit target (n=8) | 25% on time (n=8) |
Journals published in (27)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Fertility and sterility | 5 |
| Nature genetics | 3 |
| Journal of the American College of Cardiology | 2 |
| Lancet (London, England) | 2 |
| The New England journal of medicine | 2 |
Showing 5 of 27 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1,366 | 612 | 2025-12-30 |
SEC-reported annual financials (9)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 4,343,000,000 | 850,000,000 | 967,000,000 |
| 2024 | 4,372,000,000 | -1,223,000,000 | 1,169,000,000 |
| 2023 | 4,504,000,000 | -1,161,000,000 | 1,354,000,000 |
| 2022 | 4,526,000,000 | 762,000,000 | 1,185,000,000 |
| 2021 | 3,239,000,000 | 656,000,000 | 682,000,000 |
| 2019 | 3,543,000,000 | 1,002,000,000 | 647,000,000 |
| 2018 | 3,333,000,000 | 826,000,000 | 623,000,000 |
| 2017 | 2,752,000,000 | 726,000,000 | 546,000,000 |
| 2016 | 2,220,000,000 | 462,000,000 | 401,000,000 |
Financing and grant events (39)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-04-28 | Other financing | not disclosed | Sec extracted |
| 2026-01-30 | Other financing | not disclosed | Sec extracted |
| 2025-11-25 | Debt financing | 500,000,000 | Sec extracted |
| 2025-11-12 | Debt financing | 499,810,000 | Edgar offerings |
| 2025-11-10 | Other financing | not disclosed | Edgar offerings |
Showing 5 of 39 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 7 |
FDA recalls (9)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Reagent Kits/ containing flow cells, components of NextSeq 550Dx Instrument: NextSeq 550Dx High Output Reagent Kit v2.5 (75 cycles) IVD, REF: 20028870/NextSeq 550Dx HO FC Cart v2.5, 75 Cycles, REF: 20031098; NextSeq 550Dx High Output Reagent Kit v2.5 (300 cycles) IVD, REF: 20028871/NextSeq 550Dx HO FC Cart v2.5, 300 Cycles, REF: 20026365; CN NextSeq 550Dx High Output Reagent Kit v2.5 (75 cycles) IVD, REF: 20064341/CN NEXTSEQ 550Dx HO FLOW CELL V2.5, REF: 20062316; CN NextSeq 550Dx High Output Reagent Kit v2.5 (300 cycles) IVD, REF: 20064344/CN NEXTSEQ 550Dx HO FLOW CELL V2.5, REF: 20062316; CN NextSeq 550Dx Mid Output Reagent Kit v2.5 (150 cycles) IVD, 20064345/CN NEXTSEQ 550Dx MO FLOW CELL V2.5, REF: 20062530; CN NextSeq 550Dx Mid Output Reagent Kit v2.5 (300 cycles) IVD, 20064346/CN NEXTSEQ 550Dx MO FLOW CELL V2.5, REF: 20062530; /FLOWCELL, FIT FLUIDICS TESTING, REF: 15050205 | Class II | 2025-10-28 |
| NextSeq 550Dx Instrument, Catalog # 20005715, contaning Universal Copy Service software | Class II | 2023-04-05 |
| MiSeq Dx Instrument, Catalog # M70101, containing Universal Copy Service (UCS) software. | Class II | 2023-04-05 |
| illumina REF DX-410-1001 Model: MiSeq Dx illumina REF 15036706 Model: MiSeq Dx illumina REF 20014053 Model: MiSeq Dx | Class II | 2022-05-03 |
| illumina Model NextSeq 550 Dx REF 20005715 | Class II | 2022-05-03 |
Showing 5 of 9 recalls.
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Illumina, Inc. | San Diego, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | 2050 |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (18)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Duke University | Co sponsors trial with | 2 |
| Government of the United States of America | Co sponsors trial with | 2 |
| GeneDx Holdings Corp. | Co sponsors trial with | 1 |
| Janssen (France) | Co sponsors trial with | 1 |
| BIO-TECHNE Corp | Co sponsors trial with | 1 |
Showing 5 of 18 relationships.
Latest dated events (1,447)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-04-28 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-01-30 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-12-30 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-12-30 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-12-23 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 1,447 events.
CLIA clinical laboratory certificates (1)
| Lab | Certificate | Status |
|---|---|---|
| ILLUMINA LLC | Certificate of waiver | Terminated |
Biomarker capability evidence (1,813)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| NTRK1 | Diagnostics manufacturer | FDA-authorized companion diagnostic |
| NTRK2 | Diagnostics manufacturer | FDA-authorized companion diagnostic |
| RET | Diagnostics manufacturer | FDA-authorized companion diagnostic |
| Diagnostics manufacturer | FDA-authorized companion diagnostic | |
| AAAS | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
Showing 5 of 1,813 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, active development programs, approved assets, fda warning letters, fda untitled letters, fda import refusals, and biomarkers this organization publishes on.